Registry-listed formulations

ASCIMINIB HYDROCHLORIDE · chembl:CHEMBL4297220

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

23 source entries across 14 studies. This list may not include all unresolved or historical entries.

  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 20 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 20 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 20 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 20 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • AsciminibRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED GRANULES

    View study and source
  • AsciminibRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED GRANULES

    View study and source
  • ASCIMINIB HYDROCHLORIDERegistry product

    Molecular identity unconfirmed

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • ASCIMINIB HYDROCHLORIDERegistry product

    Molecular identity unconfirmed

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • AsciminibRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED GRANULES

    View study and source
  • Scemblix 40 mg film-coated tabletsRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • AsciminibRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    View study and source
  • AsciminibRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED GRANULES

    View study and source

Success Metrics

Completion Rate
50%(1/2)
Active Trials
9(75%)
Results Posted
100%(1 trials)
Terminated
1(8%)

Phase Distribution

Phase 1/2
2
17%
Phase 2
9
75%
Phase 4
1
8%

Phase Distribution

0

Early Stage

11

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1/2Combined phases
2(16.7%)
Phase 2Efficacy & side effects
9(75.0%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

9

trials recruiting

Total Trials

12

all time

Status Distribution
Active(10)
Completed(1)
Terminated(1)

Detailed Status

Recruiting8
Active, not recruiting1
Terminated1
Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
9
Success Rate
N/A
Most Advanced
Phase 1/2

Trials by Phase

Phase 1/22 (16.7%)
Phase 29 (75.0%)
Phase 41 (8.3%)

Trials by Status

recruiting867%
active_not_recruiting18%
terminated18%
not_yet_recruiting18%
completed18%

Recent Activity

9 active trials
Showing 5 of 12
recruitingphase_2

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT07354074
recruitingphase_1_2

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

NCT04925479
active_not_recruitingphase_2

Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

NCT07789574
terminatedphase_2

A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia

NCT03874858
recruitingphase_4

Asciminib Roll-over Study

NCT04877522
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07354074Phase 2

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Recruiting
NCT04925479Phase 1/2

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Recruiting
NCT07789574Phase 2

Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

Active Not Recruiting
NCT03874858Phase 2

A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia

Terminated
NCT04877522Phase 4

Asciminib Roll-over Study

Recruiting
NCT03578367Phase 2

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Completed
NCT06514534Phase 2

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Recruiting
NCT06409936Phase 2

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

Recruiting
NCT05159245Phase 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
NCT04817956Phase 2

Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
SYF1997a27528504689b2c61ab5d6d7cad8Phase 1/2

Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

Not Yet Recruiting
SYF73119a4854d945e990b2e40f46f9a350Phase 2

Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

Recruiting

All 12 trials loaded

Drug Details

Intervention Type
Type not reported
Molecule Type
Small molecule
Total Trials
12

External References

ChEMBL
CHEMBL4297220

Names & Codes

Trade Names

scemblix

Research Codes

ABL001-AAA